<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        17-584-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LUKRA 10 MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MONTELUKAST SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        71.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NEOPHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NEOPHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NEOPHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DC03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lukra 10 mg film-coated Tablet is a leukotriene receptor antagonist that blocks<br />substances called leukotrienes.<br />How Lukra 10 mg film-coated Tablets work<br />Leukotrienes cause narrowing and swelling of airways in the lungs and also<br />cause allergy symptoms. By blocking leukotrienes, Lukra 10 mg film-coated<br />Tablets improve asthma symptoms and helps control asthma and improves<br />seasonal allergy symptoms (also known as hay fever or seasonal allergic<br />rhinitis).<br />When Lukra 10 mg film-coated Tablets should be used<br />Your doctor has prescribed Lukra 10 mg film-coated Tablets to treat asthma,<br />preventing your asthma symptoms during the day and night.<br />&bull; Lukra 10 mg film-coated Tablets are used for the treatment of adults and<br />adolescents 15 years of age and older who are not adequately controlled<br />on their medication and need additional therapy.<br />&bull; Lukra 10 mg film-coated Tablets also helps prevent the narrowing of<br />airways triggered by exercise.<br />&bull; In those asthmatic patients in whom Lukra 10 mg film-coated Tablets are<br />indicated in asthma, Lukra 10 mg film-coated Tablets can also provide<br />symptomatic relief of seasonal allergic rhinitis.<br />Your doctor will determine how Lukra 10 mg film-coated Tablets should be used<br />depending on the symptoms and severity of your asthma.<br />What is asthma?<br />Asthma is a long-term disease.<br />Asthma includes:<br />&bull; difficulty breathing because of narrowed airways. This narrowing of airways<br />worsens and improves in response to various conditions.<br />&bull; sensitive airways that react to many things, such as cigarette smoke,<br />pollen, cold air, or exercise.<br />&bull; swelling (inflammation) in the lining of the airways.<br />Symptoms of asthma include: Coughing, wheezing, and chest tightness.<br />What are seasonal allergies?<br />Seasonal allergies (also known as hay fever or seasonal allergic rhinitis) are an<br />allergic response often caused by airborne pollens from trees, grasses and<br />weeds. The symptoms of seasonal allergies typically may include: stuffy, runny,<br />itchy nose; sneezing; watery, swollen, red, itchy eyes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor about any medical problems or allergies you have now or have had.<br />Do not take Lukra 10 mg film-coated Tablets<br />&bull; if you are allergic to montelukast or any of the other ingredients of this<br />medicine (listed in section 6).<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Lukra 10 mg film-coated<br />Tablets.<br />&bull; If your asthma or breathing gets worse, tell your doctor immediately.<br />&bull; Oral Montelukast is not meant to treat acute asthma attacks. If an attack<br />occurs, follow the instructions your doctor has given you. Always have your<br />inhaled rescue medicine for asthma attacks with you.<br />&bull; It is important that you or your child take all asthma medications prescribed<br />by your doctor. Lukra 10 mg film-coated Tablets should not be substituted<br />for other asthma medications your doctor has prescribed for you.<br />&bull; Any patient on anti-asthma medicines should be aware that if you develop<br />a combination of symptoms such as flu-like illness, pins and needles or<br />numbness of arms or legs, worsening of pulmonary symptoms, and/or<br />rash, you should consult your doctor.<br />&bull; You should not take acetyl-salicylic acid (aspirin) or anti-inflammatory<br />medicines (also known as non-steroidal anti-inflammatory drugs or<br />NSAIDs) if they make your asthma worse.<br />Children and adolescents<br />Do not give this medicine to children less than 15 years of age.<br />For children 2 to 5 years old, Lukra 4 mg Paediatric Chewable Tablets are<br />available.<br />For children 6 to 14 years old, Lukra 5 mg Paediatric Chewable Tablets are<br />available.<br />Other medicines and Lukra 10 mg film-coated Tablets<br />Tell your doctor or pharmacist if you are taking or have recently taken or might<br />take any other medicines including those obtained without a prescription.<br />Some medicines may affect how Lukra 10 mg film-coated Tablets work, or<br />Lukra 10 mg film-coated Tablets may affect how other medicines work.<br />Tell your doctor if you taking the following medicines before starting Lukra 10 mg<br />film-coated Tablets:<br />&bull; phenobarbital (used for treatment of epilepsy)<br />&bull; phenytoin (used for treatment of epilepsy)<br />&bull; rifampicin (used to treat tuberculosis and some other infections)<br />&bull; gemfibrozil (used for treatment of high lipid levels in plasma)<br />Lukra 10 mg film-coated Tablets with food and drink<br />Lukra 10 mg film-coated Tablets may be taken with or without food.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are<br />planning to have a baby, ask your doctor or pharmacist for advice before taking<br />Lukra 10 mg film-coated Tablets.<br />Pregnancy<br />Your doctor will assess whether you can take Lukra 10 mg film-coated Tablets<br />during this time.<br />Breast-feeding<br />It is not known if Lukra 10 mg film-coated Tablets appear in breast milk. You<br />should consult your doctor before taking Lukra 10 mg film-coated Tablets if you<br />are breast-feeding or intend to breast-feed.<br />Driving and using machines<br />Lukra 10 mg film-coated Tablets are not expected to affect your ability to drive<br />a car or operate machinery. However, individual responses to medication may<br />vary. Certain side effects (such as dizziness and drowsiness) that have been<br />reported with Montelukast may affect some patient&rsquo;s ability to drive or operate<br />machinery.<br />Lukra 10 mg film-coated Tablets contain lactose<br />If you have been told by your doctor that you have an intolerance to some<br />sugars, contact your doctor before taking this medicinal product.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>3. How to take Lukra 10 mg film-coated Tablets<br />Always take this medicine exactly as your doctor or pharmacist has told you.<br />Check with your doctor or pharmacist if you are not sure.<br />&bull; You should take only one tablet of Lukra 10 mg film-coated Tablet once a<br />day as prescribed by your doctor.<br />&bull; It should be taken even when have no symptoms or have an acute asthma<br />attack.<br />For adults and adolescents 15 years of age and older:<br />The recommended dose is one Lukra 10 mg film-coated Tablet to be taken daily<br />in the evening.<br />If you are taking Lukra 10 mg film-coated Tablets, be sure that you do not take<br />any other products that contain the same active ingredient, montelukast.<br />This medicine is for oral use.<br />You can take Lukra 10 mg film-coated Tablets with or without food.<br />If you take more Lukra 10 mg film-coated Tablets than you should<br />Contact your doctor immediately for advice.<br />There were no side effects reported in the majority of overdose reports. The&nbsp;&nbsp;most frequently occurring symptoms reported with overdose in adults and&nbsp;children included abdominal pain, sleepiness, thirst, headache, vomiting and<br />hyperactivity.<br />If you forget to take Lukra 10 mg film-coated Tablets<br />Try to take Lukra 10 mg film-coated Tablets as prescribed. However, if you miss<br />a dose, just resume the usual schedule of one tablet once daily.<br />Do not take a double dose to make up for a forgotten dose.<br />If you stop taking Lukra 10 mg film-coated Tablets<br />Lukra 10 mg film-coated Tablets can treat your asthma only if you continue to<br />take it. It is important to continue taking Lukra 10 mg film-coated Tablets for as<br />long as your doctor prescribes. It will help control your asthma.<br />If you have any further questions on the use of this medicine, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />In clinical studies with Montelukast 10 mg film-coated tablets, the most<br />commonly reported side effects (occurring in at least 1 of 100 patients and less<br />than 1 of 10 patients treated) thought to be related to Montelukast 10 mg<br />film-coated tablets were:<br />&bull; abdominal pain<br />&bull; headache<br />These were usually mild and occurred at a greater frequency in patients treated<br />with Montelukast than placebo (a pill containing no medication).<br />The frequency of possible side effects listed below is defined using the<br />following convention:<br />Very common: may affect more than 1 in 10 people<br />Common: may affect up to 1 in 10 people<br />Uncommon: may affect up to 1 in 100 people<br />Rare: may affect up to 1 in 1,000 people<br />Very rare: may affect up to 1 in 10,000 people<br />Not known: frequency cannot be estimated from the available data<br />Additionally, while the medicine has been on the market, the following have<br />been reported:<br />&bull; upper respiratory infection (Very common)<br />&bull; increased bleeding tendency (Rare)<br />&bull; allergic reactions including swelling of the face, lips, tongue, and/or throat<br />which may cause difficulty in breathing or swallowing (Uncommon)<br />&bull; behaviour and mood related changes [dream abnormalities, including<br />nightmares, trouble sleeping, sleep walking, irritability, feeling anxious,<br />restlessness, agitation including aggressive behaviour or hostility,<br />depression (Uncommon); tremor, disturbance in attention, memory<br />impairment (Rare); hallucinations, disorientation, suicidal thoughts and<br />actions (Very rare)]<br />&bull; dizziness, drowsiness, pins and needles/numbness, seizure (Uncommon)<br />&bull; palpitations (Rare)<br />&bull; nosebleed (Uncommon), swelling (inflammation) of the lungs (Very rare)<br />&bull; diarrhoea, nausea, vomiting (Common); dry mouth, indigestion<br />(Uncommon)<br />&bull; hepatitis (inflammation of the liver) (Very rare)<br />&bull; rash (Common); bruising, itching, hives (Uncommon); tender red lumps<br />under the skin most commonly on your shins (erythema nodosum), severe<br />skin reactions (erythema multiforme) that may occur without warning (Very<br />rare)<br />&bull; joint or muscle pain, muscle cramps (Uncommon)<br />&bull; fever (Common); weakness/tiredness, feeling unwell, swelling (Uncommon)<br />In asthmatic patients treated with montelukast, very rare cases of a combination<br />of symptoms such as flu-like illness, pins and needles or numbness of arms and<br />legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss<br />syndrome) have been reported. You must tell your doctor right away if you get<br />one or more of these symptoms (See section 2).<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This<br />includes any possible side effects not listed in this leaflet.<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />&bull; Do not use this medicine after the expiry date which is stated on the carton<br />and blister after EXP. The expiry date refers to the last day of that month.<br />&bull; Store below 30&deg;C.<br />&bull; Store in the original package in order to protect from light and moisture.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask<br />your pharmacist how to throw away medicines you no longer use. These<br />measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>. Further information<br />What Lukra 10 mg film-coated Tablets contain?<br />The active substance is montelukast.<br />&bull; Each film-coated tablet contains Montelukast Sodium equivalent to 10 mg<br />of Montelukast.<br />&bull; The other ingredients are Lactose Monohydrate, Mannitol, Hydroxy Propyl<br />Cellulose, Cellulose Microcrystalline, Croscarmellose Sodium, Magnesium<br />Stearate and Opadry Yellow 20A520007.<br />Composition of Opadry Yellow 20A520007: HPMC 2910/Hypromellose 6<br />Cp, Hydroxy Propyl Cellulose, Titanium Dioxide, Carnuaba wax, Iron Oxide<br />Yellow and Iron Oxide Red.<br />What Lukra 10 mg film-coated Tablets look like?<br />Beige, rounded square-shaped, film coated tablets debossed with &#39;MS1&#39; on one<br />side and plain on other side.<br />How supplied:<br />Lukra 10 mg film-coated Tablets are supplied in Blister pack.<br />&bull; Pack of 30 tablets (3x10&rsquo;s blisters).<br />&bull; Pack of 100 tablets (10x10&rsquo;s blisters).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                . Further information
What Lukra 10 mg film-coated Tablets contain?
The active substance is montelukast.
• Each film-coated tablet contains Montelukast Sodium equivalent to 10 mg
of Montelukast.
• The other ingredients are Lactose Monohydrate, Mannitol, Hydroxy Propyl
Cellulose, Cellulose Microcrystalline, Croscarmellose Sodium, Magnesium
Stearate and Opadry Yellow 20A520007.
Composition of Opadry Yellow 20A520007: HPMC 2910/Hypromellose 6
Cp, Hydroxy Propyl Cellulose, Titanium Dioxide, Carnuaba wax, Iron Oxide
Yellow and Iron Oxide Red.
What Lukra 10 mg film-coated Tablets look like?
Beige, rounded square-shaped, film coated tablets debossed with 'MS1' on one
side and plain on other side.
How supplied:
Lukra 10 mg film-coated Tablets are supplied in Blister pack.
• Pack of 30 tablets (3x10’s blisters).
• Pack of 100 tablets (10x10’s blisters).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Neopharma</p><p>Plot A-1 89-95, ICAD, Mussafah,<br />P.O. Box 72900, Abu Dhabi, UAE.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>القرص المغلف لوكرا ١٠ ملجم هو مضاد مستقبل الليوكوترين الذي يحصر مواداً<br />تدعى الليكوترينات.<br />كيف تعمل أقراص مغلفة لوكرا ١٠ ملجم<br />تسبب الليكوترينات تض ّ يق وتورم المسالك الهوائية في الرئتين وتتسبب أيضاً<br />في ظهور أعراض الحساسية. من خلال حصر الليكوترينات، تقلل أقراص مغلفة لوكرا<br />١٠ ملجم أعراض الربو وتساعد في التحكم في هذا المرض وتقلل أعراض<br />الحساسية الموسمية (تُعرف أيضاً بحمى الكلأ أو التهاب الأنف الأرجي الموسمي).<br />متى يجب استخدام أقراص مغلفة لوكرا ١٠ ملجم<br />لقد وصف لك طبيبك أقراص مغلفة لوكرا ١٠ ملجم لعلاج الربو، حيث يمنع ظهور<br />أعراض الربو خلال الليل والنهار.<br />&bull; تستخدم أقراص ١٠ ملجم لعلاج المرضى البالغين والمراهقين الذين يبلغون ١٥ عاماً<br />&bull; وأكبر والذين لا تكفي أدويتهم للتحكم في المرض ويحتاجون علاجاً إضافياً.<br />&bull; تساعد أقراص مغلفة لوكرا ١٠ ملجم أيضاً على منع تض ّ يق المسالك الهوائية الذي<br />يثيره اﻟﻤﺠهود البدني.<br />&bull; للمرضى المصابين بالربو الذين وصفت لهم أقراص مغلفة لوكرا ١٠ ملجم لعلاج<br />الربو، يمكن لهذه الأقراص أن تخفف من أعراض التهاب الأنف الأرجي الموسمي.<br />سيحدد طبيبك كيفية استخدام أقراص لوكرا ١٠ ملغ بحسب الأعراض و ِ حدة الربو<br />عندك.<br />ما هو الربو؟<br />الربو مرض طويل المدى.<br />يتضمن الربو:<br />&bull; صعوبة في التنفس بسبب تض ّ يق المسالك الهوائية. يسوء ويتحسن هذا الت ّ ضيق<br />في المسالك الهوائية بحسب الاستجابة لظروف مختلفة.<br />&bull; المسالك الهوائية الحساسة التي تتفاعل مع أشياء عديدة، مثل دخان السجائر،<br />أو اللقاح، أو الهواء البارد، أو اﻟﻤﺠهود البدني.<br />&bull; تورم (التهاب) بطانة المسالك الهوائية.<br />تتضمن أعراض الربو: سعال، وصفير، وضيق الصدر.<br />ما هي الحساسية الموسمية؟<br />الحساسية الموسمية (تُعرف أيضاً بحمى الكلأ أو التهاب الأنف الأرجي الموسمي) هي<br />استجابة تحسسية كثيراً ما تتسبب بها حبوب اللقاح المنقولة بالهواء من الأشجار،<br />والعشب والحشائش. قد تتضمن أعراض الحساسية الموسمية عادة:<br />انسداد الأنف، والرشح، والحكة في الأنف، والعطس، وتدمع العينين، وتورم العينين،<br />واحمرار العينين، وحكة في العينين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أخبر طبيبك بشأن أي مشاكل طبية أو حساسية لديك الآن أو سبقت لك الإصابة<br />بها.<br />لا تتناول أقراص مغلفة لوكرا ١٠ ملجم<br />&bull; إذا كنت مصاباً بحساسية لمادة المونتيلوكاست أو أي من مكونات هذا الدواء<br />.( (المدرجة في القسم ٦<br />التحذيرات والاحتياطات<br />تحدث مع طبيبك أو الصيدلي قبل تناول أقراص مغلفة لوكرا ١٠ ملجم:<br />&bull; إذا ساء الربو أو التنفس عندك، أخبر طبيبك على الفور.<br />&bull; مادة المونتيلوكاست التي يتم تناولها عن طريق الفم غير مخصصة لعلاج أزمات<br />الربو الحادة. في حالة حدوث أزمة، اتبع التعليمات التي وصفها الطبيب لك. اجعل<br />الدواء المستنشق الخاص بك لعلاج أزمات الربو الطارئة دائماً بحوزتك.<br />&bull; من الهام لك أو لطفلك تناول جميع أدوية الربو التي وصفها الطبيب. يجب عدم<br />استخدام أقراص مغلفة لوكرا ١٠ ملجم كبديل عن أدوية الربو الأخرى التي وصفها<br />الطبيب لك.<br />&bull; يجب على أي مريض يتناول أدوية مضادة للربو الانتباه إذا ما ظهر عليه مجموعة<br />أعراض تشبه مرض الإنفلونزا، أو وخز دبابيس وإبر، أو خدر في الذراعين أو الساقين، أو<br />تدهور الأعراض الرئوية، و/أو طفح جلدي، فيجب عليه استشارة الطبيب.<br />&bull; يجب علييك عدم تناول حمض أسيتيل ساليسيليك (الأسبرين) أو الأدوية المضادة<br />للالتهابات (تُعرف أيضاً بالعقاقير غير السترويدية المضادة للالتهابات أو<br />(مضادات الالتهاب اللاستيرويدية) إذا جعلت الأزمة عندك أسوأ.<br />الأطفال والمراهقون<br />لا تعط هذا الدواء للأطفال الأصغر من ١٥ عاماً.<br />للأطفال بعمر سنتين إلى ٥ سنوات، تتوافر أقراص مضغ لوكرا ٤ ملجم للأطفال.<br />للأطفال بعمر ٦ أعوام إلى ١٤ عاماً، تتوافر أقراص مضغ لوكرا ٥ ملجم للأطفال.<br />الأدوية الأخرى وأقراص مغلفة لوكرا ١٠ ملجم<br />أخبر طبيبك أو الصيدلي إن كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى، بما<br />في ذلك تلك الأدوية التي تُصرف بدون وصفة طبية.<br />قد تؤثر بعض الأدوية على الطريقة التي تعمل بها أقراص مغلفة لوكرا ١٠ ملجم، أو<br />قد تؤثر أقراص مغلفة لوكرا ١٠ ملجم على الطريقة التي تعمل بها الأدوية الأخرى.<br />أخبر طبيبك إذا ما كنت تتناول الأدوية التالية قبل البدء بتناول أقراص مغلفه لوكرا ١٠<br />ملغ:<br />&bull; فينوباربيتال (يستخدم لعلاج الصرع)<br />&bull; فينيتوين (يستخدم لعلاج الصرع)<br />&bull; ريفامبيسين (يُستخدم في علاج السل وبعض الالتهابات الأخرى)<br />أقراص لوكرا ١٠ ملجم المغلفة مع الطعام والشراب<br />&bull; جيمفيبروزيل (يُستخدم في علاج ارتفاع مستويات شحوم الدم) يمكن تناول أقراص<br />مغلفة لوكرا ١٠ ملجم مع الطعام أو بدونه.<br />الحمل والرضاعة الطبيعية<br />إذا كن ِ ت حاملاً أو ترضعين رضاعة طبيعية، أو تعتقدين أن ِ ك قد تكونين حاملاً<br />أو تخططين للحمل، اطلبي المشورة من طبيبك أو الصيدلي قبل تناول أقراص مغلفة<br />لوكرا ١٠ ملجم.<br />الحمل<br />س ُ يقيم الطبيب إذا ما كان بإمكانك تناول أقراص مغلفة لوكرا ١٠ ملجم خلال هذه<br />الفترة.<br />الرضاعة الطبيعية<br />من غير المعروف إذا ما كانت أقراص مغلفة لوكرا ١٠ ملجم تُفرز في حليب الأم. يجب<br />علي ِ ك استشارة طبيبك قبل تناول أقراص مغلفة لوكرا ١٠ ملجم إذا ما كن ِ ت ترضعين<br />أو تنوين إرضاع طفلك رضاعة طبيعية.<br />القيادة واستخدام الآلات<br />من غير المتوقع أن تؤثر أقراص مغلفة لوكرا ١٠ ملجم على قدرتك على القيادة أو<br />تشغيل أي آلة. إلا أن الاستجابات الفردية للدواء قد تتباين. قد تؤثر آثار جانبية محددة<br />(مثل ال ّ دوار والنعاس) ارتبطت باستخدام مادة المونتيلوكاست على قدرة المريض على<br />القيادة أو تشغيل الآلات&nbsp;تحتوي أقراص مغلفة لوكرا ١٠ ملجم على اللاكتوز،<br />فإذا أخبرك طبيبك أنك تعاني من عدم تحمل لبعض أنواع السكر، اتصل بطبيبك قبل<br />تناول هذا المنتج الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول هذا الدواء دائماً على النحو الذي يصفه طبيبك أو الصيدلي.<br />استشر طبيبك أو الصيدلي إذا لم تكن متأك ً دا.<br />&bull; يجب عليك تناول قرص مغلف واحد من لوكرا ١٠ ملجم مرة واحدة يومياً على<br />النحو الذي يصفه لك طبيبك.<br />&bull; يجب تناوله حتى مع عدم ظهور أي أعراض أو عند الإصابة بأزمة ربو حادة.<br />للبالغين والمراهقين من عمر ١٥ عاماً وأكثر:<br />الجرعة الموصى بها هي قرص مغلف واحد من لوكرا ١٠ ملجم مرة واحدة يومياً في<br />المساء.<br />إذا كنت تتناول أقراص مغلفه لوكرا ١٠ ملغ، تأكد من عدم تناول أي منتجات أخرى<br />تحتوى على نفس المكون الفعال، وهي مادة المونتيلوكاست.<br />يُتناول هذا الدواء عن طريق الفم.<br />يمكنك تناول أقراص مغلفه لوكرا ١٠ ملغ مع الطعام أو بدونه.<br />في حال تناول كمية أكثر من اللازم من أقراص مغلفة لوكرا ١٠ ملجم<br />يجب عليك الاتصال بطبيبك على الفور لاستشارته.<br />لم ترد أي آثار جانبية في أغلبية تقارير الجرعة المفرطة. تضمنت الأعراض الأكثر شيوعاً<br />التي أُبلغ عنها في حالة الجرعات المفرطة في البالغين والأطفال الشعور بألم في&nbsp;البطن، والنعاس، والعطش، والصداع، والقيء، والنشاط المفرط.<br />إن نسيت تناول أقراص مغلفة لوكرا ١٠ ملجم<br />حاول تناول أقراص مغلفة لوكرا ١٠ ملجم على النحو الموصوف. لكن إذا ف ّ وت جرعة،<br />واصل النظام المعتاد من تناول قرص واحد يومياً.<br />لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.<br />الانقطاع عن تناول أقراص مغلفة لوكرا ١٠ ملجم<br />يمكن لأقراص مغلفة لوكرا ١٠ ملجم علاج الربو عندك فقط إذا داومت على تناولها. من<br />المهم المداومة على تناول أقراص مغلفة لوكرا ١٠ ملجم للمدة التي يصفها الطبيب،<br />حيث يساعد ذلك على التحكم في الربو عندك.<br />إن كان لديك أي استفسارات أخرى حول استخدام هذا الدواء فاسأل طبيبك أو<br />الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية يمكن لهذا الدواء أن يسبب آثاراً جانبية، على الرغم من أنه ليس<br />بالضرورة أن يعاني منها الجميع.<br />في الدراسات الإكلينيكية على مونتيلوكاست أقراص ١٠ ملجم المغلفة، كانت الآثار<br />الجانبية الأكثر شيوعاً (تحدث على الأقل في ١ من كل ١٠٠ مريض وأقل من ١ من كل ١٠<br />مرضى يعالجون) التي يُعتقد أنها متصلة بمونتيلوكاست أقراص مغلفة ١٠ ملجم هي:<br />&bull; ألم البطن<br />&bull; الصداع<br />كانت هذه الآثار في الأغلب طفيفة وظهرت بمعدل أعلى على المرضى الذين يتلقون<br />العلاج بمادة المونتيلوكاست مقارنة بالبلاسيبو (أقراص لا تحتوي على أي دواء).<br />ُ حدد معدل ظهور الآثار الجانبية المحتملة الواردة أدناه باستخدام الاصطلاحات التالية:<br />شائعة جداً: قد تؤثر على أكثر من ١ من كل ١٠ أشخاص<br />شائعة: قد تؤثر على ١ من كل ١٠ أشخاص<br />غير شائعة: قد تؤثر على ١ من كل ١٠٠ شخص<br />نادرة: قد تؤثر على ١ من كل ١٠٠٠ شخص<br />نادرة جداً: قد تؤثر على ١ من كل ١٠٠٠٠ شخص<br />غير معروف: لا يمكن تقدير مدى التكرار من البيانات المتوفرة بالإضافة إلى ذلك، في<br />الوقت الذي كان فيه الدواء مطروحاً في الأسواق، تم الإبلاغ عن الآثار الجانبية التالية:<br />&bull; التهاب في الجزء العلوي التنفسي (شائع جداً)<br />&bull; ميل متزايد للنزيف (نادر)<br />&bull; ردود فعل تحسسية تتضمن تورم الوجه، والشفتين، واللسان، و/أو الحلق مما قد يسبب<br />صعوبة في التنفس أو البلع (غير شائع)<br />&bull; تغيرات مزاجية وسلوكية [أحلام مضطربة، تشمل الكوابيس، وصعوبة في النوم،<br />والسير أثناء النوم، والتهيج، والشعور بالقلق، والتململ، والهياج بما في ذلك<br />السلوك العدائي أو العدوانية، والاكتئاب (غير شائع)؛ الرعشة، واضطراب الانتباه،<br />وضعف الذاكرة (نادر)؛ هلوسة، وتشوش، وأفكار وتصرفات انتحارية (نادر جداً)]<br />&bull; دوّار، ونعاس، ووخز بالإبر والدبابيس/خدر، ونوبات (غير شائع)<br />&bull; خفقان (نادر)<br />&bull; النزف الأنفي (غير شائع)، وتورم (التهاب) الرئتين (نادر جداً)<br />&bull; إسهال، وغثيان، وقيء (شائع)، وجفاف الفم، وعسر الهضم (غير شائع)<br />&bull; التهاب كبدي (التهاب الكبد) (نادر جداً)<br />&bull; طفح جلدي (شائع)، وتكدم، وحكة، وشرى (غير شائع)، وكتل حمراء لينة تحت الجلد<br />في الأغلب في مقدمة السيقان (الحمامى العقدية)، وردود فعل جلدية حادة<br />(الحمامى متعددة الأشكال) التي قد تحدث بدون إنذار (نادر جداً)<br />&bull; ألم مفصلي أو عضلي، وتشنجات عضلية (غير شائع)<br />&bull; حمى (شائع)، وضعف/إجهاد، وشعور بالاعتلال، وتورم (غير شائع)<br />في المرضى المصابين بالربو الذين يتلقون العلاج بمادة المونتيلوكاست، أبلغ عن حالات<br />نادرة جداً من مجموعة أعراض تشبه مرض الإنفلونزا، أو وخز دبابيس وإبر، أو خدر في<br />الذراعين أو الساقين، أو تدهور أعراض رئوية و/أو طفح جلدي (متلازمة شيرغ ستراوس).<br />يجب عليك إبلاغ الطبيب على الفور في حالة ظهور واحد أو أكثر من هذه الأعراض<br />.( (راجع القسم ٢<br />إذا ظهرت عليك أي أعراض جانبية، تحدث مع طبيبك أو الصيدلي أو الممرضة. وذلك<br />يتضمن أي أعراض جانبية محتملة غير مدرجة في هذه النشرة.<br />للإبلاغ عن الأعراض الجانبية:<br />&bull; المملكة العربية السعودية:</p><p>&bull; دول الخليج الأخرى:<br />الرجاء الإتصال بالمؤسسات والهيئات الوطنية لكل دولة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.<br />&bull; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على العلبة الكرتونية<br />يشير تاريخ انتهاء الصلاحية .(EXP) &quot; والشريط بعد عبارة &quot;تاريخ انتهاء الصلاحية<br />إلى آخر يوم من ذلك الشهر.<br />&bull; يُخزن في درجة حرارة أقل من ٣٠ &deg; درجة مئوية.<br />&bull; يُحفظ في العبوة الأصلية لحمايته من الضوء والرطوبة.<br />&bull; لا تتخلص من أي أدوية في ماء الصرف الصحي أو مع اﻟﻤﺨلفات المنزلية. اسأل<br />الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد<br />هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما هي محتويات أقراص مغلفة لوكرا ١٠ ملجم؟<br />المادة الفعالة هي المونتيلوكاست.<br />&bull; يحتوي كل قرص مغلف على مونتيلوكاست الصوديوم بما يعادل ١٠ ملجم من مادة<br />المونتيلوكاست.<br />&bull; المكونات الأخرى هي لاكتوز أحادي الهيدرات، مانيتول، كروس كارميلوز الصوديوم،<br />هيدروكسي بروبيل سيليولوز، سيليولوز دقيق التبلور، كروس كارميلوز الصوديوم،<br />.٢٠A ستيارات المغنيسيوم، وأوبادري أصفر ٥٢٠٠٠٧<br />/ ٢٠ : هيدروكسي بروبيل ميثيل سليلوز ٢٩١٠ A تركيب الأوبادري الأصفر ٥٢٠٠٠٧<br />هيدروكسي بروبيل سيليولوز، ثاني أكسيد التيتانيوم، شمع ،Cp هيبروميلوز ٦<br />كرنوبي، أكسيد الحديد الأصفر وأكسيد الحديد الأحمر.<br />كيف تبدو أقراص مغلفة لوكرا ١٠ ملجم؟<br />&quot;MS أقراص بيج مغلفة على شكل مربع مدور الأطراف، محفور على أحد جانبيها &quot; 1<br />والجانب الآخر فارغ.<br />كيف يتم توريدها:<br />تباع أقراص مغلفة لوكرا ١٠ ملجم في عبوات تحتوي على شرائط.<br />&bull; علبة تحتوي على ٣٠ قرصاً ( ٣ شرائط يحتوي كل منها على ١٠ أقراص).<br />&bull; علبة تحتوي على ١٠٠ قرص ( ١٠ شرائط يحتوي كل منها على ١٠ أقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ما هي محتويات أقراص مغلفة لوكرا ١٠ ملجم؟<br />المادة الفعالة هي المونتيلوكاست.<br />&bull; يحتوي كل قرص مغلف على مونتيلوكاست الصوديوم بما يعادل ١٠ ملجم من مادة<br />المونتيلوكاست.<br />&bull; المكونات الأخرى هي لاكتوز أحادي الهيدرات، مانيتول، كروس كارميلوز الصوديوم،<br />هيدروكسي بروبيل سيليولوز، سيليولوز دقيق التبلور، كروس كارميلوز الصوديوم،<br />.٢٠A ستيارات المغنيسيوم، وأوبادري أصفر ٥٢٠٠٠٧<br />/ ٢٠ : هيدروكسي بروبيل ميثيل سليلوز ٢٩١٠ A تركيب الأوبادري الأصفر ٥٢٠٠٠٧<br />هيدروكسي بروبيل سيليولوز، ثاني أكسيد التيتانيوم، شمع ،Cp هيبروميلوز ٦<br />كرنوبي، أكسيد الحديد الأصفر وأكسيد الحديد الأحمر.<br />كيف تبدو أقراص مغلفة لوكرا ١٠ ملجم؟<br />&quot;MS أقراص بيج مغلفة على شكل مربع مدور الأطراف، محفور على أحد جانبيها &quot; 1<br />والجانب الآخر فارغ.<br />كيف يتم توريدها:<br />تباع أقراص مغلفة لوكرا ١٠ ملجم في عبوات تحتوي على شرائط.<br />&bull; علبة تحتوي على ٣٠ قرصاً ( ٣ شرائط يحتوي كل منها على ١٠ أقراص).<br />&bull; علبة تحتوي على ١٠٠ قرص ( ١٠ شرائط يحتوي كل منها على ١٠ أقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>نيوفارما</p><p>٥ ، مدينة أبوظبي -٨٩ قطعة رقم إيه- ١<br />الصناعية، مصفح، ص.ب. ٧٢٩٠٠ ، أبوظبي، إ.ع.م.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lukra Tablets 10 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains Montelukast Sodium equivalent to 10 mg Montelukast.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast Sodium is indicated in the treatment of asthma as add-on therapy in those<br />patients with mild to moderate persistent asthma who are inadequately controlled on<br />inhaled corticosteroids and in whom &ldquo;as-needed&rdquo; short acting &beta;-agonists provide inadequate<br />clinical control of asthma. In those asthmatic patients in whom Montelukast Sodium is<br />indicated in asthma, Montelukast Sodium can also provide symptomatic relief of seasonal<br />allergic rhinitis. Montelukast Sodium is also indicated in the prophylaxis of asthma in which<br />the predominant component is exercise-induced bronchoconstriction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The dosage for adults and adolescents 15 years of age and older with asthma, or with<br />asthma and concomitant seasonal allergic rhinitis, is one 10 mg tablet daily to be taken in<br />the evening.<br />General recommendations.<br />The therapeutic effect of Montelukast Sodium on parameters of asthma control occurs within<br />one day. Montelukast Sodium may be taken with or without food. Patients should be<br />advised to continue taking Montelukast Sodium even if their asthma is under control, as well<br />as during periods of worsening asthma. Montelukast Sodium should not be used<br />concomitantly with other products containing the same active ingredient, montelukast.</p><p>No dosage adjustment is necessary for the elderly, or for patients with renal insufficiency, or<br />mild to moderate hepatic impairment. There are no data on patients with severe hepatic<br />impairment. The dosage is the same for both male and female patients.<br />Therapy with Montelukast Sodium in relation to other treatments for asthma.<br />Montelukast Sodium can be added to a patient&#39;s existing treatment regimen.<br />Inhaled corticosteroids: Treatment with Montelukast Sodium can be used as add-on therapy<br />in patients when inhaled corticosteroids plus &quot;as needed&quot; short acting &beta;-agonists provide<br />inadequate clinical control. Montelukast Sodium should not be abruptly substituted for<br />inhaled corticosteroids.<br />Paediatric population<br />Do not give Montelukast Sodium to children less than 15 years of age. The safety and<br />efficacy of Montelukast Sodium tablets in children less than 15 years has not been<br />established.<br />5 mg chewable tablets are available for paediatric patients 6 to 14 years of age.<br />4 mg chewable tablets are available for paediatric patients 2 to 5 years of age.<br />4 mg granules are available for paediatric patients 6 months to 5 years of age.<br />Method of administration<br />Oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised never to use oral montelukast to treat acute asthma attacks and<br />to keep their usual appropriate rescue medication for this purpose readily available. If an<br />acute attack occurs, a short-acting inhaled &beta;-a gonist should be used. Patients should seek<br />their doctor&#39;s advice as soon as possible if they need more inhalations of short-acting &beta;-a<br />gonists than usual.<br />Montelukast should not be substituted abruptly for inhaled or oral corticosteroids.<br />There are no data demonstrating that oral corticosteroids can be reduced when montelukast<br />is given concomitantly.<br />In rare cases, patients on therapy with anti-asthma agents including montelukast may<br />present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis&nbsp;consistent with Churg-Strauss syndrome, a condition which is often treated with systemic<br />corticosteroid therapy. These cases usually, but not always, have been associated with the<br />reduction or withdrawal of oral corticosteroid therapy. The possibility that leukotriene<br />receptor antagonists may be associated with emergence of Churg-Strauss syndrome can<br />neither be excluded nor established. Physicians should be alert to eosinophilia,<br />vasculiticrash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy<br />presenting in their patients. Patients who develop these symptoms should be reassessed<br />and their treatment regimens evaluated.<br />Treatment with montelukast does not alter the need for patients with aspirin-sensitive<br />asthma to avoid taking aspirin and other non-steroidal anti-inflammatory drugs.<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency<br />or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast may be administered with other therapies routinely used in the prophylaxis and<br />chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of<br />montelukast did not have clinically important effects on the pharmacokinetics of the<br />following medicinal products: theophylline, prednisone, prednisolone, oral contraceptives<br />(ethinyl estradiol/ norethindrone 35/1), terfenadine, digoxin and warfarin.<br />The area under the plasma concentration curve (AUC) for montelukast was decreased<br />approximately 40% in subjects with co-administration of phenobarbital. Since montelukast<br />is metabolised by CYP 3A4, 2C8, and 2C9, caution should be exercised, particularly in<br />children, when montelukast is co-administered with inducers of CYP 3A4, 2C8, and 2C9,<br />such as phenytoin, phenobarbital and rifampicin.<br />In vitro studies have shown that montelukast is a potent inhibitor of CYP 2C8. However,<br />data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a<br />probe substrate representative of medicinal products primarily metabolized by CYP 2C8)<br />demonstrated that montelukast does not inhibit CYP 2C8 in vivo. Therefore, montelukast is<br />not anticipated to markedly alter the metabolism of medicinal products metabolised by this<br />enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide.)&nbsp;In vitro studies have shown that montelukast is a substrate of CYP 2C8, and to a less<br />significant extent, of 2C9, and 3A4. In a clinical drug-drug interaction study involving<br />montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) gemfibrozil increased<br />the systemic exposure of montelukast by 4.4-fold. No routine dosage adjustment<br />ofmontelukast is required upon co-administration with gemfibrozil or other potent inhibitors<br />of CYP 2C8, but the physician should be aware of the potential for an increase in adverse<br />reactions.<br />Based on in vitro data, clinically important drug interactions with less potent inhibitors of<br />CYP 2C8 (e.g., trimethoprim) are not anticipated. Co-administration of montelukast with<br />itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the<br />systemic exposure of montelukast.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Animal studies do not indicate harmful effects with respect to effects on pregnancy or<br />embryonal/fetal development.<br />Limited data from available pregnancy databases do not suggest a causal relationship<br />between Montelukast Sodium and malformations (i.e. limb defects) that have been rarely<br />reported in worldwide post marketing experience.<br />Montelukast Sodium may be used during pregnancy only if it is considered to be clearly<br />essential.<br />Use during lactation<br />Studies in rats have shown that montelukast is excreted in milk. It is not known if<br />montelukast is excreted in human milk.<br />Montelukast Sodium may be used in breast-feeding only if it is considered to be clearly<br />essential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast has no or negligible influence on the ability to drive and use machines.<br />However, individuals have reported drowsiness or dizziness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast has been evaluated in clinical studies as follows:<br /> 10 mg film-coated tablets in approximately 4000 adult and adolescent asthmatic<br />patients 15 years of age and older.<br /> 10 mg film-coated tablets in approximately 400 adult and adolescent asthmatic<br />patients with seasonal allergic rhinitis 15 years of age and older.<br /> 5 mg chewable tablets in approximately 1750 paediatric asthmatic patients 6 to 14<br />years of age.<br />The following drug-related adverse reactions in clinical studies were reported commonly<br />(&ge;1/100 to &lt;1/10) in asthmatic patients treated with montelukast and at a greater<br />incidence than in patients treated with placebo:<br />Body System Class<br />Adult and Adolescent Patients<br />15 years and older<br />(two 12-week studies;<br />n=795)<br />Paediatric Patients<br />6 to 14 years old<br />(one 8-week study; n=201)<br />(two 56-week studies; n=615)<br />Nervous system<br />disorders<br />headache headache<br />Gastro-intestinal<br />disorders<br />abdominal pain<br />With prolonged treatment in clinical trials with a limited number of patients for up to 2 years<br />for adults, and up to 12 months for paediatric patients 6 to 14 years of age, the safety<br />profile did not change.<br />Tabulated list of Adverse Reactions<br />Adverse reactions reported in post-marketing use are listed, by System Organ Class and<br />specific Adverse Reactions, in the table below. Frequency Categories were estimated based<br />on relevant clinical trials.</p><p>system Organ Class Adverse Experience Term Frequency Category*<br />Infections and infestations upper respiratory infection&dagger; Very Common<br />Blood and lymphatic system<br />disorders<br />increased bleeding tendency Rare<br />Immune system disorders<br />hypersensitivity reactions<br />including anaphylaxis<br />Uncommon<br />hepatic eosinophilic infiltration Very Rare<br />Psychiatric disorders<br />dream abnormalities including<br />nightmares, insomnia,<br />somnambulism, anxiety, agitation<br />including aggressive behaviour or<br />hostility, depression,<br />psychomotor hyperactivity<br />(including irritability,<br />restlessness, tremor&sect;)<br />Uncommon<br />disturbance in attention, memory<br />impairment<br />Rare<br />Psychiatric disorders<br />hallucinations, disorientation,<br />suicidal thinking and behaviour<br />(suicidality)<br />Very Rare<br />Nervous system disorder<br />dizziness, drowsiness<br />paraesthesia/hypoesthesia,<br />seizure<br />Uncommon<br />Cardiac disorders palpitations Rare<br />Respiratory, thoracic and<br />mediastinal disorders<br />epistaxis Uncommon<br />Churg-Strauss Syndrome (CSS) Very Rare<br />Pulmonary eosinophilia Very Rare<br />Gastrointestinal disorders<br />diarrhoea&Dagger;, nausea&Dagger;, vomiting&Dagger; Common<br />dry mouth, dyspepsia Uncommon<br />Hepatobiliary disorders<br />elevated levels of serum<br />transaminases (ALT, AST)<br />Common</p><p>system Organ Class Adverse Experience Term Frequency Category*<br />Hepatitis (including cholestatic,<br />hepatocellular, and mixed-pattern<br />liver injury).<br />Very Rare<br />Skin and subcutaneous tissue<br />disorders<br />rash&Dagger; Common<br />bruising, urticaria, pruritus Uncommon<br />angiooedema Rare<br />erythema nodosum, erythema<br />multiforme<br />Very Rare<br />Musculoskeletal, connective<br />tissue and bone disorders<br />arthralgia, myalgia including<br />muscle cramps<br />Uncommon<br />General disorders and<br />administration site conditions<br />pyrexia&Dagger; Common<br />asthenia/fatigue, malaise,<br />oedema<br />Uncommon<br />*Frequency Category: Defined for each Adverse Reaction by the incidence reported in<br />the clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10),<br />Uncommon (&ge;1/1000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1000), Very Rare (&lt;1/10,000).<br />&dagger; This adverse experience, reported as Very Common in the patients who received<br />montelukast, was also reported as Very Common in the patients who received placebo in<br />clinical trials.<br />&Dagger; This adverse experience, reported as Common in the patients who received montelukast,<br />was also reported as Common in the patients who received placebo in clinical trials.<br />&sect; Frequency Category: Rare&nbsp;To report any side effect(s):<br />&bull; Saudi Arabia:<br /> The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />o Other GCC States:<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In chronic asthma studies, montelukast has been administered at doses up to 200 mg/day<br />to adult patients for 22 weeks and in short term studies, up to 900 mg/day to patients for<br />approximately one week without clinically important adverse experiences.<br />There have been reports of acute overdose in post-marketing experience and clinical studies<br />with montelukast. These include reports in adults and children with a dose as high as 1000<br />mg (approximately 61 mg/kg in a 42 month old child). The clinical and laboratory findings<br />observed were consistent with the safety profile in adults and paediatric patients. There<br />were no adverse experiences in the majority of overdose reports.</p><p>Symptoms of overdose<br />The most frequently occurring adverse experiences were consistent with the safety profile of<br />montelukast and included abdominal pain, somnolence, thirst, headache, vomiting, and<br />psychomotor hyperactivity.<br />Management of overdose<br />No specific information is available on the treatment of overdose with montelukast. It is<br />not known whether montelukast is dialysable by peritoneal- or haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1. Pharmacodynamics:<br />Pharmacotherapeutic group: Leukotriene receptor antagonist<br />ATC-code: R03D C03<br />Mechanism of action<br />The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory eicosanoids released<br />from various cells including mast cells and eosinophils. These important pro-asthmatic<br />mediators bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT1)<br />receptor is found in the human airway (including airway smooth muscle cells and airway<br />macrophages) and on other pro-inflammatory cells (including eosinophils and certain<br />myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and<br />allergic rhinitis. In asthma, leukotriene-mediated effects include bronchoconstriction,<br />mucous secretion, vascular permeability, and eosinophil recruitment. In allergic rhinitis,<br />CysLTs are released from the nasal mucosa after allergen exposure during both early- and<br />late-phase reactions and are associated with symptoms of allergic rhinitis. Intranasal<br />challenge with CysLTs has been shown to increase nasal airway resistance and symptoms of<br />nasal obstruction.<br />Pharmacodynamic effects<br />Montelukast is an orally active compound which binds with high affinity and selectivity to<br />the CysLT1 receptor. In clinical studies, montelukast inhibits bronchoconstriction due to<br />inhaled LTD4 at doses as low as 5 mg. Bronchodilation was observed within 2 hours of oral<br />administration. The bronchodilation effect caused by a &beta;-agonist was additive to that caused<br />by montelukast. Treatment with montelukast inhibited both early- and late-phase<br />bronchoconstriction due to antigen challenge. Montelukast, compared with placebo,<br />decreased peripheral blood eosinophils in adult and paediatric patients. In a separate study,<br />treatment with montelukast significantly decreased eosinophils in the airways (as measured<br />in sputum) and in peripheral blood while improving clinical asthma control.<br />Clinical efficacy and Safety<br />In studies in adults, montelukast, 10 mg once daily, compared with placebo, demonstrated<br />significant improvements in morning FEV1 (10.4% vs 2.7% change from baseline), AM peak<br />expiratory flow rate (PEFR) (24.5 L/min vs 3.3 L/min change from baseline), and significant<br />decrease in total &beta;-agonist use (-26.1% vs -4.6% change from baseline). Improvement in&nbsp;Patient-reported daytime and nighttime asthma symptoms scores was significantly better<br />than placebo.<br />Studies in adults demonstrated the ability of montelukast to add to the clinical effect of<br />inhaled corticosteroid (% change from baseline for inhaled beclometasone plus montelukast<br />vs beclometasone, respectively for FEV1: 5.43% vs 1.04%; &beta;-agonist use: -8.70% vs<br />2.64%). Compared with inhaled beclometasone (200 &mu;g twice daily with a spacer device),<br />montelukast demonstrated a more rapid initial response, although over the 12-week study,<br />beclometasone provided a greater average treatment effect (% change from baseline for<br />montelukast vs beclometasone, respectively for FEV1: 7.49% vs 13.3%; &beta;-agonist use: -<br />28.28% vs -43.89%). However, compared with beclometasone, a high percentage of<br />patients treated with montelukast achieved similar clinical responses (e.g., 50% of patients<br />treated with beclometasone achieved an improvement in FEV1 of approximately 11% or<br />more over baseline while approximately 42% of patients treated with montelukast achieved<br />the same response).<br />A clinical study was conducted to evaluate montelukast for the symptomatic treatment of<br />seasonal allergic rhinitis in adult and adolescent asthmatic patients 15 years of age and<br />older with concomitant seasonal allergic rhinitis. In this study, montelukast 10 mg tablets<br />administered once daily demonstrated a statistically significant improvement in the Daily<br />Rhinitis Symptoms score, compared with placebo. The Daily Rhinitis Symptoms score is the<br />average of the Daytime Nasal Symptoms score (mean of nasal congestion, rhinorrhea,<br />sneezing, nasal itching) and the Nighttime Symptoms score (mean of nasal congestion upon<br />awakening, difficulty going to sleep, and nighttime awakenings scores). Global evaluations<br />of allergic rhinitis by patients and physicians were significantly improved, compared with<br />placebo. The evaluation of asthma efficacy was not a primary objective in this study.<br />In an 8-week study in paediatric patients 6 to 14 years of age, montelukast 5 mg once<br />daily, compared with placebo, significantly improved respiratory function (FEV1 8.71% vs<br />4.16% change from baseline; AM PEFR 27.9 L/min vs 17.8 L/min change from baseline) and<br />decreased &quot;as-needed&quot; &beta;-agonist use (-11.7% vs +8.2% change from baseline).<br />Significant reduction of exercise-induced bronchoconstriction (EIB) was demonstrated in a<br />12-week study in adults (maximal fall in FEV1 22.33% for montelukast vs 32.40% for<br />placebo; time to recovery to within 5% of baseline FEV1 44.22 min vs 60.64 min). This<br />effect was consistent throughout the 12-week study period. Reduction in EIB was also&nbsp;demonstrated in a short term study in paediatric patients (maximal fall in FEV1 18.27% vs<br />26.11%; time to recovery to within 5% of baseline FEV1 17.76 min vs 27.98 min). The<br />effect in both studies was demonstrated at the end of the once-daily dosing interval.<br />In aspirin-sensitive asthmatic patients receiving concomitant inhaled and/or oral<br />corticosteroids, treatment with montelukast, compared with placebo, resulted in significant<br />improvement in asthma control (FEV1 8.55% vs -1.74% change from baseline and decrease<br />in total &beta;-agonist use -27.78% vs 2.09% change from baseline).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Montelukast is rapidly absorbed following oral administration. For the 10 mg film-coated<br />tablet, the mean peak plasma concentration (Cmax) is achieved 3 hours (Tmax) after<br />administration in adults in the fasted state. The mean oral bioavailability is 64%. The oral<br />bioavailability and Cmax are not influenced by a standard meal. Safety and efficacy were<br />demonstrated in clinical trials where the 10 mg film-coated tablet was administered without<br />regard to the timing of food ingestion.<br />For the 5 mg chewable tablet, the Cmax is achieved in 2 hours after administration in adults<br />in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a<br />standard meal.<br />Distribution<br />Montelukast is more than 99% bound to plasma proteins. The steady-state volume of<br />distribution of montelukast averages 8-11 litres. Studies in rats with radiolabelled<br />montelukast indicate minimal distribution across the blood-brain barrier. In addition,<br />concentrations of radiolabelled material at 24 hours post-dose were minimal in all other<br />tissues.<br />Biotransformation.<br />Montelukast is extensively metabolised. In studies with therapeutic doses, plasma<br />concentrations of metabolites of montelukast are undetectable at steady state in adults and<br />children.&nbsp;Cytochrome P450 2C8 is the major enzyme in the metabolism of montelukast. Additionally<br />CYP 3A4 and 2C9 may have a minor contribution, although itraconazole, an inhibitor of CYP<br />3A4, was shown not to change pharmacokinetic variables of montelukast in healthy subjects<br />that received 10 mg montelukast daily. Based on in vitro results in human liver microsomes,<br />therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4,<br />2C9, 1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of<br />montelukast is minimal.<br />Elimination<br />The plasma clearance of montelukast averages 45 ml/min in healthy adults. Following an<br />oral dose of radiolabelled montelukast, 86% of the radioactivity was recovered in 5-day<br />faecal collections and &lt;0.2% was recovered in urine. Coupled with estimates of montelukast<br />oral bioavailability, this indicates that montelukast and its metabolites are excreted almost<br />exclusively via the bile.<br />Characteristics in patients<br />No dosage adjustment is necessary for the elderly or mild to moderate hepatic insufficiency.<br />Studies in patients with renal impairment have not been undertaken. Because montelukast<br />and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to<br />be necessary in patients with renal impairment. There are no data on the pharmacokinetics<br />of montelukast in patients with severe hepatic insufficiency (Child-Pugh score &gt;9).<br />With high doses of montelukast (20- and 60-fold the recommended adult dose), decrease in<br />plasma theophylline concentration was observed. This effect was not seen at the<br />recommended dose of 10 mg once daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal toxicity studies, minor serum biochemical alterations in ALT, glucose,<br />phosphorus and triglycerides were observed which were transient in nature. The signs of<br />toxicity in animals were increased excretion of saliva, gastrointestinal symptoms, loose<br />stools and ion imbalance. These occurred at dosages which provided &gt;17-fold the systemic<br />exposure seen at the clinical dosage. In monkeys, the adverse effects appeared at doses<br />from 150 mg/kg/day (&gt;232-fold the systemic exposure seen at the clinical dose). In<br />animal studies, montelukast did not affect fertility or reproductive performance at systemic<br />exposure exceeding the clinical systemic exposure by greater than 24-fold. A slight<br />decrease in pup body weight was noted in the female fertility study in rats at 200&nbsp;mg/kg/day (&gt;69-fold the clinical systemic exposure). In studies in rabbits, a higher<br />incidence of incomplete ossification, compared with concurrent control animals, was seen<br />at systemic exposure &gt;24-fold the clinical systemic exposure seen at the clinical dose. No<br />abnormalities were seen in rats. Montelukast has been shown to cross the placental barrier<br />and is excreted in breast milk of animals.<br />No deaths occurred following a single oral administration of montelukast sodium at doses<br />up to 5,000 mg/kg in mice and rats (15,000 mg/m2 and 30,000 mg/m2 in mice and rats,<br />respectively), the maximum dose tested. This dose is equivalent to 25,000 times the<br />recommended daily adult human dose (based on an adult patient weight of 50 kg).<br />Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light<br />spectra at doses up to 500 mg/kg/day (approximately &gt;200-fold based on systemic<br />exposure).<br />Montelukast was neither mutagenic in in vitro and in vivo tests nor tumorigenic in rodent<br />species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>S. NO. MATERIAL FUNCTION<br />Dry Mixing<br />1. Lactose Monohydrate (Impalpable) Ph.Eur Diluent<br />2. Mannitol (Pearlitol 25C) Ph.Eur. Diluent<br />3. Croscarmellose Sodium (Ac-di-Sol) Ph.Eur. Disintegrant<br />Granulation<br />4. Hydroxy propyl Cellulose (Klucel LF) Ph.Eur. Binder<br />5. Purified Water IHS/USP/ Ph.Eur. Solvent<br />6. Purified Water (If required) IHS/USP/ Ph.Eur. Solvent<br />Extra Granular<br />7. Cellulose Microcrystalline (Avicel PH 112) Ph.Eur. Diluent<br />8. Croscarmellose Sodium (Ac-di-Sol) Disintegrant<br />9.<br />Magnesium Stearate (or) Magnesium Stearate (Liga-MF-<br />2V-VEG) Ph.Eur.<br />Lubricant<br />Film Coating (12% w/w Suspension)<br />10. Opadry Yellow 20A520007 IHS Coating Agent<br />11. Purified Water@ IHS/USP/Ph.Eur Solvent<br />COMPOSITION OF OPADRY YELLOW 20A520007<br />S.<br />No<br />Ingredients Function<br />a) HPMC 2910/Hypromellose 6 Cp USP, Ph.Eur., JP Film-Forming<br />b) Hydroxypropyl Cellulose NF, Ph.Eur, JP, FCC Film forming<br />c) Titanium Dioxide USP, FCC, Ph.Eur, JP Opacifier<br />d) Carnauba wax NF, Ph.Eur Polishing agent<br />e) Iron Oxide Yellow NF, JPE Colorant<br />f) Iron Oxide Red NF, JPE Colorant</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lukra tablets 10 mg are packed in Alu/Alu blisters and placed in a printed carton along with<br />a pack insert.<br />Pack size: 30&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                6.6 Manufacturer:
Neopharma,
Plot No, A1 89-95, Industrial City of Abu Dhabi,
Mussafah, P.O.Box: 72900
Abu Dhabi, UAE.
6.7 Marketing Authorization Holder:
Neopharma,
Plot No, A1 89-95, Industrial City of Abu Dhabi,
Mussafah, P.O.Box: 72900
Abu Dhabi, UAE.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                17 December 2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>